Italia markets closed

Celcuity Inc. (CELC)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
16,83-0,52 (-3,00%)
Alla chiusura: 04:00PM EDT
16,83 0,00 (0,00%)
Dopo ore: 04:02PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente17,35
Aperto17,49
Denaro16,74 x 200
Lettera16,85 x 100
Min-Max giorno16,67 - 17,55
Intervallo di 52 settimane8,39 - 22,19
Volume79.685
Media Volume245.359
Capitalizzazione512,526M
Beta (5 anni mensile)0,87
Rapporto PE (ttm)N/D
EPS (ttm)-2,69
Prossima data utili15 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A28,60
  • GlobeNewswire

    Celcuity to Host Virtual Science Day for Investors

    Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa® (darolutamide) in patients with mCRPCEvent to be webcast from 10:00 a.m. – 12:00 p.m. ET on September 21, 2023 MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuin

  • GlobeNewswire

    Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

    MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant prostate cancer (mCRPC). As part of the supply agreement, Bayer will provide Nubeqa to C

  • GlobeNewswire

    Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

    - Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Celcuity can proceed